Aducanumab produced a clinically meaningful benefit in association with amyloid lowering

Ítems similars

• Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
  per: Sheila Seleri Assunção, et al.
  Publicat: (2022-04-01)
• Open Peer Commentary to “Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019”
  per: Sabbagh, Marwan Noel, et al.
  Publicat: (2020)
• Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval
  per: Tolar, Martin, et al.
  Publicat: (2020)
• Critical Appraisal of Amyloid Lowering Agents in AD
  per: Decourt, Boris, et al.
  Publicat: (2021)
• Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β
  per: Arndt, Joseph W., et al.
  Publicat: (2018)